Similarly, a randomized, double-blinded, placebo-controlled phase II trial reported that tiragolumab (anti-TIGIT antibody) plus atezolizumab (anti-PD-L1 antibody) significantly improved objective response rate (ORR), PFS and OS in patients with newly diagnosed metastatic PD-L1-positive NSCLC compared with placebo plus atezolizumab [21]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.